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Background: Different conditions make the proximal airways susceptible to tussigenic stimuli in the chronic cough
(CC) syndrome. Leukotrienes can be implicated in the inflammatory mechanism at play in it. Montelukast is a
selective cysteinyl-leukotriene receptor antagonist with proven effectiveness in patients with asthma. The aim of our
real-life pilot study was to use montelukast to relieve cough symptoms in patients with CC allegedly due to the
two frequent causes other than asthma – upper airway cough syndrome and gastroesophageal reflux (GER).
Methods: 14 consecutive patients with CC were evaluated before and after 2 weeks of treatment with montelukast
10 mg daily. Cough was assessed by validated cough questionnaire. Questionnaires regarding the presence of
gastroesophageal reflux were also completed. Cough reflex sensitivity to incremental doubling concentrations of
citric acid and capsaicin was measured. Lung function, airway hyperresponsiveness and exhaled breath temperature
(EBT), a non-invasive marker of lower airway inflammation, were evaluated to exclude asthma as an underlying
cause. Thorough upper-airway examination was also conducted. Cell counts, eosinophil cationic protein (ECP),
lactoferrin, myeloperoxidase (MPO) were determined in blood to assess systemic inflammation.
Results: Discomfort due to cough was significantly reduced after treatment (P < 0.001). Cough threshold for
capsaicin increased significantly (P = 0.001) but not for citric acid. The values of lactoferrin and ECP were
significantly reduced, but those of MPO rose. EBT and pulmonary function were not significantly affected by the
treatment.
Conclusion: Patients with CC due to upper airway cough syndrome or gastroesophageal reflux (GER) but not
asthma reported significant relief of their symptoms after two weeks of treatment with montelukast. ECP, lactoferrin,
MPO altered significantly, highlighting their role in the pathological mechanisms in CC. Clinical trial ID at
Clinicaltrials.gov is NCT01754220.
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Chronic cough (CC) is typically defined as cough that per-
sists for longer than 8 weeks and its management presents
a challenge for the clinician. Ruling out a plethora of less
frequent pathologies, three conditions remain that ac-
count for 92% of CC in immunocompetent, nonsmoking
subjects: 1) upper airway cough syndrome (UACS), also* Correspondence: ted.popov@gmail.com
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unless otherwise stated.referred to as postnasal drip syndrome, 2) asthma and 3)
gastroesophageal reflux (GER) [1,2]. Cough may be a
prominent symptom of asthma and management accord-
ing to the Global Initiative of Asthma (GINA) guidelines
usually suppresses it. Similarly, diagnosis and treatment of
UACS and GER would in most cases alleviate or abolish
bothersome cough.
The underling mechanisms of cough have been exten-
sively investigated. The afferent part of the cough reflex
consists of mainly two types of receptors: predominant
rapidly adapting receptors (RARs) that respond primarilyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hypertonic saline, and citric acid) and non-myelinated
C-fibers that characteristically respond to chemical and
inflammatory stimuli such as histamine, prostaglandins,
substance P and capsaicin [3,4]. Citric acid is the most
widely used acid tussigen, which works upon sensory fast-
conducting nerve endings as well as nociceptors and A-
delta fibers [5]. Capsaicin is known to induce cough in a
reproducible and dose-dependent way and acts mainly via
transient receptor potential vanilloid receptors [6]. Both
types of receptors seem to be at play in subjects with CC,
their relative involvement shaping the individual pattern
of the condition.
Cough receptors are triggered differently in CC patho-
genesis. In UACS secretions containing inflammatory me-
diators are thought to stimulate proximal airway receptors
inducing cough. This umbrella term includes sinusitis, al-
lergic and non-allergic rhinitis, (postinfectious rhinitis,
rhinitis medicamentosa, vasomotor rhinitis, rhinitis due to
physical or chemical irritants) [3]. The exact mechanisms
for cough attributable to GER are still debated but the
most probable ones are on one hand distal esophageal acid
exposure that stimulates an esophageal-tracheobronchial
cough reflex via the branches of the vagus nerve, and
microaspiration of esophageal contents into the laryn-
gopharynx and trachea eliciting also symptoms like dys-
phonia and bitter taste [7,8]. Furthermore, esophageal
dysmotility occurs with ensuing dysregulation of the
aerodigestive reflexes [9].
Cysteinyl - leukotrienes (CysLTs) LTC4, LTD4 and LTE4
are produced from arachidonic acid through the 5-
lipoxygenase pathway within inflammatory and structural
cells, including mast cells, eosinophils, basophils, dendritic
cells, lymphocytes, bronchial epithelial and smooth muscle
cells [10]. They exert their proinflammatory, bronchocon-
strictive and mucosecretory effects through interaction
with their receptors, CysLT1R and CysLT2R [11]. The pos-
sible mechanism of CysLTs in CC could be direct since it
has been shown that CysLTs stimulate the release of sub-
stance P and other tachykinins [12], and indirect, by exert-
ing their bronchoconstrictive effects or inducing secretions
from the inflamed tissues affecting both types of cough re-
ceptors. Montelukast ingested orally is a selective and po-
tent cysteinyl - leukotriene receptor antagonist (CysLTRA)
that exerts its action by blocking CysLT1Rs. It has already
passed the scrutiny of many elaborate randomized con-
trolled trials and its efficacy and safety in treating patients
with asthma have been proven. LTRAs are now on the list
of drugs recommended for asthma treatment by the Global
Initiative for Asthma guidelines (GINA) [13]. It has also
been speculated that the range of action of montelukast
stretches out in any type of inflammatory process in which
leukotrienes are involved, acting also in a CysLT1R-inde-
pendent manner [14]. Its effectiveness in rhinitis has beenshown [15], but there is paucity of data about the other
conditions underlying CC [16,17]. Nevertheless, random-
ized controlled trials, although recognized as the ‘gold
standard’ for establishing efficacy, operate in an idealized
environment and can only measure efficacy in limited, arti-
ficially selected populations. Thus, our idea was to interfere
as little as possible in the average patients’ population that
comes to see the doctor and to observe what effects mon-
telukast might have in patients with CC which is not due
to asthma.
In this pilot study we wanted to explore in real life set-
tings the effectiveness of two weeks treatment with mon-
telukast in patients with chronic cough on the patients’
perception of discomfort due to cough coupled with
measurement of cough threshold to recognized tussigenic
stimuli. Moreover, we wanted to see whether changes in
local airway and systemic inflammatory markers paralleled
the subjective effects of montelukast treatment.
Methods
Study design and patients
The study was conducted as a pilot observational real
life trial. Fourteen consecutive out-patients referred to
the Clinic of Allergy and Asthma in Sofia, Bulgaria were
enrolled. They had subjective and objective measure-
ments taken at the beginning and after two weeks
treatment period with montelukast (Alvokast, Alvogen
Pharma Bulgaria) 10 mg in the evening. We have chosen
two weeks as an arbitrary duration of treatment short-
ening the 4 week period that other investigators used
for patients with cough-variant asthma [18,19]. Patients
ranged between 15 and 69 years in age, 9 were women
and all met the inclusion criterion of having cough for
8 weeks or longer and the exclusion criteria of current
use of ACE-inhibitors, use of systemic and inhaled ste-
roids in the last 4 weeks, concomitant severe disease,
COPD, pregnancy and current smoking. All patients
had normal chest radiographs. They underwent stand-
ard examinations to substantiate inflammatory changes
in the oral and nasal cavities, assessments of their lung
function, airway responsiveness and atopic state. Based
on the results from this diagnostic algorithm we ex-
cluded patients in the spectrum of asthmatic conditions.
All of the patients signed an informed consent. The study
was approved by the local Ethics committee of Alexander’s
University Hospital in Sofia.
Patients were asked to fill in a self-administered vali-
dated questionnaire on the impact of cough on quality
of life, a modified Bulgarian version of Leicester Cough
Questionnaire (LCQ) [20] on both visits and only on the
first visit they were to fill in the Frequency Scale for the
Symptoms of GER (FSSG) questionnaire to account for
the possibility of GER playing a role in their cough com-
plaints [21]. Scores above 8 coupled with complaints of
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ther suggestive of concomitant reflux pathology in 5 of
the patients enrolled in the study. Although the use of
objective tests for verification of GER complaints is rea-
sonable, till present day there is no unanimous view on
this in regard to cough assessment and their routine use
in investigation of GER cannot be recommended [22].
Measurements
Pulmonary function tests were performed (Schiller Spirovit
SP – 10 Spirometer) and showed normal volume and
dynamic lung parameters (Table 1) with negative bron-
chodilator/bronchoconstrictor response. Tests aimed at
characterizing the cough reflex and airway and systemic
inflammation were carried out before onset and after of
the two weeks montelukast treatment following the
same sequence. Exhaled breath temperature (EBT), a
surrogate marker of airway inflammation, was assessed
with portable breath thermometer (X-Halo, Delmedica
Investments LTD, Singapore) according to a standard-
ized procedure [23]. The evaluation of cough threshold
to the tussigenic substances citric acid and capsaicin
was done with due resemblance to ERS guidelines on
the assessment of cough [24]. In brief, six serial dilu-
tions were attained before every measurement from pre-
pared stock solutions of citric acid 1000 mmol/l and
capsaicin 100 μmol/l. For the delivery of the tussigenic
substances we used Omron MicroAir portable ultra-
sonic nebulizer and the patients were asked to take five
consecutive tidal breaths of a given concentration. The
patients were blinded for the order of delivery and the
concentration of capsaicin or citric acid that produced




Variables format and values
Age [years] Mean = 43, Standard deviation = 17
Gender [number (%)] Females = 9 (64), Males = 5 (36)
Atopy [number (%)] 3 (14)




GER [number (%)] 5 (36)
Duration of cough (weeks) Mean = 27, Range = 8 ÷ 72
LCQ score before treatment Mean = 12.4, Standard deviation = 3.36
FSSG score Mean = 9.9, Standard deviation = 7.8
FVC% predicted before
treatment
Mean = 110.6, Standard deviation = 19.9
FEV1% predicted before
treatment
Mean = 111.2, Standard deviation = 19.2
EBT before treatment Mean = 34.46, Standard deviation = 0.54For economic reasons and for the convenience of our out-
patients both cough threshold measurements were per-
formed on the same day, although we tried to leave the
maximal possible interval between them to minimize the
effect of tachyphylaxis [25]. Although current unanimity
on C2 or C5 as the preferred end-point has not been
reached, most of the published studies often report both
values, but not infrequently C5 alone is reported. For the
sake of facilitating the statistical analysis we equalized the
concentrations with indices (from 1 being the highest
dilution to 7 being the stock concentration). The sys-
temic markers of inflammation were high sensitivity C-
reactive protein (hsCRP), eosinophil cationic protein
(ECP), lactoferrin (LF) and myeloperoxidase (MPO).
High sensitivity C-reactive protein (hsCRP) was assessed in
a centralized laboratory using latex immunoturbidimetric
method (GIESSE Diagnostics s.r.l., Rome, Italy). ECP was
measured by sandwich ELISA ECP using a reagent of
RADIM S.p.A., Roma, Italy. Lactoferrin and MPO were
evaluated by means of immunoenzymatic test using re-
agents of AESKU Diagnostics, Wendelsheim, Germany.
Statistical analysis
Demographic data were analyzed using standard descrip-
tive analysis. All numerical data sets were checked for nor-
mality by using the Kolmogorov-Smirnov test to allow
further processing by parametric or non-parametric tests.
Pre-/post- treatment comparisons and pretreatment cor-
relations were sought. P < 0.05 was accepted for two-tailed
significance. SPSS 16 software package was used for the
analysis.
Results
The characteristics of the patients are shown on Table 1.
None of them reported any side effect attributable to
the drug. Subjectively all of them had complete or al-
most complete resolution of the cough complaints. The
total LCQ score showed significant improvement from
12.4 (mean) ± 3.4 (standard deviation) to 16.6 ± 3.1 score,
P < 0.001 (Figure 1).
Interestingly, there was a highly significant inverse
correlation between initial LCQ scores and GER scores:
R = −0.73, P = 0.003 (Figure 2). Lung function parame-
ters FVC% predicted (110.6 ± 5.3 vs. 108.8 ± 6.1), FEV1%
predicted (111 ± 5.1 vs. 107 ± 4.5) and EBT (34.46 ± 0.14
vs. 34.53 ± 0.12) did not change significantly after treat-
ment. Nevertheless, cough threshold exhibited differen-
tial change for capsaicin (C5 more pronounced than C2)
but for citric acid not substantial enough to reach sig-
nificance (Figures 3 & 4).
The results from the laboratory workup showed decrease
in lactoferrin (from 9.94 ± 0.46 to 9.01 ± 0.49, p < 0.05) and
ECP (from 17.33 ± 2.91 to 11.29 ± 1.70, p < 0.05) levels.
However, MPO levels significantly raised (7.87 ± 0.46 vs.
Figure 1 Leicester cough Questionnaire (LCQ) scores before
and after treatment.
Figure 3 Cough indices for citric acid before and after treatment.
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eosinophil count (P = 0.985) altered enough to reach statis-
tical significance.
Discussion
Chronic cough is a burdensome health problem for pa-
tients and diagnostic and treatment challenge for the
managing physicians. While cough in asthma is usually
brought under control by treatment as outlined in the
GINA guidelines, the treatment of UACS and GER as
triggers of cough, occurring separately or concomitantly,
has not been well standardized. Moreover, in both of these
conditions cough can be the sole presenting symptom
[26,27]. CysLTRAs have been approved for additional
treatment of asthma and their effect of cough variant
asthma has also been explored [16,18,19,28]. Nevertheless,
the effectiveness of montelukast and other CysLTRAs hasFigure 2 Inverse correlation between LCQ and FSSG scores.not been investigated in patients with other most frequent
CC triggers. Cysteinyl-leukotrienes are pivotal inflamma-
tory mediators which exert their biological effects through
interaction with their receptors and are known to mediate
plenty of pathological processes including submucosal
edema, airway smooth muscle cell proliferation and con-
traction, mucus production, recruitment and activation of
inflammatory cells, mainly eosinophils [29]. Several stud-
ies indicate elevated levels of Cys-LTs in induced sputum
in different conditions causing chronic cough [30,31]. Our
results indicate an effect of the CysLTRA montelukast on
different markers of inflammation in the heterogeneous
group of 14 consecutive patients with CC referred to our
tertiary clinic.
ECP as a marker of eosinophil activation showed a de-
crease resulting from the treatment, which can possiblyFigure 4 Cough indices for capsaicin before and
after treatment.
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not out of the limits, eosinophil priming is still present
in patients with UACS, some of them with underlying
allergic rhinitis and atopy.
Lactoferrin is a multifunctional protein that among other
things is present in the secondary granules of neutrophil
granulocytes. Our results showed significant reduction of
the lactoferrin levels which might be interpreted to be due
to the ability of leukotrienes to stimulate lactoferrin release
from neutrophils [32]. Hence, their blockage will prevent
them from exerting this effect.
Myeloperoxidase is most abundantly expressed in neu-
trophils and its major role is to aid in microbial killing
and facilitate neutrophilic inflammation. We observed
that MPO values rose after treatment contrary to com-
mon sense expectations. Several studies have attempted
to elucidate the interplay between MPO and leukotri-
enes [33,34]. In the light of these the increase in MPO
can be explained with the role of MPO in inactivation of
leukotrienes. Montelukast as a Cys-LT1R blocker only af-
fects the mechanism of their action not the amounts of
CysLTs. As a consequence of the receptor blockage un-
utilized leukotrienes could pile up and a feedback in-
crease of MPO would be needed to inactivate them.
This is an interesting interrelation that to our knowledge
has not been described so far.
As opposed to the systemic biomarkers of inflamma-
tion, montelukast did not affect the outcomes of the
study related to the lower airways, EBT and lung func-
tion tests. EBT is an airway inflammatory marker which
reflects the thermal rise due to inflammation mainly in
the intrathoracic airways. The initial values of EBT and
the lung function tests were fairly uniform and did not
change significantly after treatment, suggesting that our
patient population was rather homogeneous and free
from lower airway involvement. Indeed, only one patient
had a positive methacholine test in the moderate range.
Additionally, he did not present with any other symp-
toms characteristic for asthmatic state.
Two week therapy with montelukast selectively de-
creased the cough reflex sensitivity to capsaicin with
high statistical significance, and while a decrease was
outlined also for citric acid, it was not significant. Al-
legedly, montelukast lowers the inflammatory load mak-
ing the cough receptors less prone to activation. The
significant decrease of the cough threshold sensitivity to
capsaicin could be interpreted as a much more specific
effect of montelukast on the inflammatory substances
implicated in CC such as histamine, bradykinin, prosta-
glandins and substance P than the non-specific mechan-
ical and acidic irritants [28,35].
None of our patients had typical GER symptoms alone.
It may be speculated that altered state of the tissues of
laryngeal and pharyngeal region in UACS may enhancethe tussigenic effects of GER supporting the notion of
pathological cough reflex hypersensitivity [22].
In our study we made use of a real-life design to test the
potential of a well-known therapeutic agent with good
safety profile to help patients with CC. It can only be
viewed as preliminary proof-of-concept to be further elab-
orated by blinded controlled trials. We realize that our
pilot study has limitations, mostly related to its sample size
and lack of “gold standard” procedures for diagnostic con-
firmation. The starting point of the approach we assumed
was that in real life physicians rarely have the time and re-
sources to carry out all investigations to confirm or to rule
out the separate options. We thought of montelukast as a
safe means to try out in CC patients without firm signs of
undisputed pathology like asthma, UACS, GERD or other
organic causes. If negative within the time span used in this
study, this strategy should have been substituted by further
diagnostic/therapeutic attempts. It was an attempt to con-
firm an initial hypothesis for local and systemic involve-
ment of cysteinyl- leukotrienes in different configurations
of CC. As montelukast is applied through the oral route
and has systemic anti-inflammatory effects, it may have ad-
vantages over routinely prescribed antitussive drugs with-
out such activity. If the leading bothersome symptom of
cough is suppressed in the treated patients, the further
elucidation and management of the condition should
continue along the same line basically pointing to UACS
alone or with superimposed features of GER. Thus
montelukast could be a valuable therapeutic alternative
with proven safety profile and overall cost-effectiveness.
A different study design is needed to assess the optimal
duration of montelukast treatment and the sustainabil-
ity of its therapeutic effect.
Conclusion
In conclusion our pilot study supports the feasibility of
montelukast as initial exploratory treatment of patients
with chronic cough in the primary care setting. This could
be a new probationary approach, but its benefits and po-
tential pitfalls need to be further evaluated.
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